Cortisporin TC
Generic: COLISTIN SULFATE, NEOMYCIN SULFATE, THONZONIUM BROMIDE AND HYDROCORTISONE ACETATE
Basic Information
Manufacturer
Endo USA, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
AURICULAR (OTIC)
FDA Set ID
9c6fc1c7-3350-42ae-b999-aca48e704bb1
Indications & Usage
INDICATIONS AND USAGE Cortisporin ® TC Otic is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics.
Warnings
WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti.
The risk is greater with prolonged use.
Therapy should be limited to 10 consecutive days (See PRECAUTIONS-General ).
Patients being treated with eardrops containing neomycin should be under close clinical observation.
Cortisporin ® TC Otic should be used cautiously in any patient with a perforated tympanic membrane.
Neomycin sulfate may cause cutaneous sensitization.
A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known.
Discontinue promptly if sensitivity or irritation occurs.
When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin.
The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal.
Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed.
These symptoms regress quickly on withdrawing the medication.
Neomycin containing applications should be avoided for the patient thereafter.
The risk is greater with prolonged use.
Therapy should be limited to 10 consecutive days (See PRECAUTIONS-General ).
Patients being treated with eardrops containing neomycin should be under close clinical observation.
Cortisporin ® TC Otic should be used cautiously in any patient with a perforated tympanic membrane.
Neomycin sulfate may cause cutaneous sensitization.
A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known.
Discontinue promptly if sensitivity or irritation occurs.
When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin.
The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal.
Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed.
These symptoms regress quickly on withdrawing the medication.
Neomycin containing applications should be avoided for the patient thereafter.
Adverse Reactions
ADVERSE REACTIONS Neomycin occasionally causes skin sensitization.
Ototoxicity (see WARNINGS section) and nephrotoxicity have also been reported.
Adverse reactions have occurred with topical use of antibiotic combinations.
Exact incidence figures are not available since no denominator of treated patients is available.
The reaction occurring most often is allergic sensitization.
In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.
In another study the incidence was found to be approximately 1%.
The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
For medical advice about adverse reactions contact your medical professional.
To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Ototoxicity (see WARNINGS section) and nephrotoxicity have also been reported.
Adverse reactions have occurred with topical use of antibiotic combinations.
Exact incidence figures are not available since no denominator of treated patients is available.
The reaction occurring most often is allergic sensitization.
In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.
In another study the incidence was found to be approximately 1%.
The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
For medical advice about adverse reactions contact your medical professional.
To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.